News & Events

News


Thursday December 07, 2017

Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Live Audio Webcast Will be on December 14, 2017 SAN DIEGO, Dec. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 11:00 a.m. ET on Thursday, Dec. 14, 2017, in New York City. Timothy P. Coughlin, Vice President Finance of Neurocrine Biosciences, will present at the conference.  The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences, ...


Monday December 04, 2017

Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial - Additional Data Presented from INGREZZA Clinical Studies Show Efficacy Across Adult Patient Groups SAN DIEGO, Dec. 4, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the KINECT 4 Phase III open-label study demonstrate that once-daily INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), improved TD symptoms through 48 weeks of open-label treatment and was generally well tolerated. TD is characterized by uncontrollable, abno...


Wednesday November 29, 2017

Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting

Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic SAN DIEGO, Nov. 29, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the open-label KINECT 4 Phase III study of INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the Hot Topics Session at the American College of Neuropsychopharmacology (ACNP) Annual Meeting December 3-7 in Palm Springs, California. "Neurocrine is committed to helping patients who struggle with both tardive dyskinesia and their psychiatric condition," said Christopher O'Brien, M.D., Chief Medical...


Tuesday November 21, 2017

Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast Will be on November 28, 2017 SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 29th Annual Piper Jaffray Healthcare Conference at 12:00 p.m. ET on Tuesday, Nov. 28, 2017, in New York City. Timothy P. Coughlin, Vice President Finance of Neurocrine Biosciences, will present at the conference.  The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences, Inc. Neurocrine Bioscienc...


Monday November 20, 2017

Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer

SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO). "We are very pleased to welcome Matt Abernethy to the Neurocrine team as our Chief Financial Officer," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "Matt's strong background in commercial finance and investor relations will be vital to Neurocrine as we continue to execute on our commercialization and clinical plans in support of our commitment to relieve patient suffering and enhance...

Events